HCA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HCA Healthcare Inc is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, and favorable news sentiment outweigh the minor insider selling activity. The stock's technical indicators, while neutral to slightly bullish, support a long-term investment perspective.
The MACD is above 0 and positively contracting, indicating a potential bullish trend. The RSI is neutral at 36.644, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 467.596, and resistance is at 508.027. The stock is trading near its pivot point of 487.812, suggesting consolidation.
Analysts have raised price targets significantly, with the highest target at $635, citing strong fundamentals, AI-driven efficiency gains, and industry-leading margins.
HCA's Q4 2025 financials showed robust growth in revenue (+6.72% YoY), net income (+30.60% YoY), and EPS (+44.58% YoY).
Recent news highlights HCA's operational excellence, including recognition for clinical performance and integration of care systems.
Insider selling has increased significantly by 1487.91% over the last month.
The stock's implied volatility percentile is high at 95.2, indicating potential price swings.
HCA Healthcare delivered strong financial results in Q4 2025, with revenue increasing to $19.51 billion (+6.72% YoY), net income rising to $1.878 billion (+30.60% YoY), and EPS growing to $8.14 (+44.58% YoY). Gross margin also improved slightly to 80.07%.
Analysts are overwhelmingly positive on HCA, with multiple firms raising price targets recently. RBC Capital, TD Cowen, UBS, and others highlight HCA's strong execution, AI-driven efficiency, and robust EBITDA growth. The highest price target is $635, with most ratings being Buy or Outperform.
